文献速递前列腺癌

根治性前列腺切除术后寡复发前列腺癌转移导向治疗的复发预测因素

Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2023-03-04

这项双中心回顾性研究纳入2006至2020年间根治性前列腺切除术后因寡复发前列腺癌接受转移导向治疗(MDT)的211例连续患者,分析5年影像学无进展生存、无转移生存等结局及无转移生存的预后因素。结果显示5年无转移生存为68%,cN1与cM+患者5年无转移生存分别为83%与51%(p<0.001),cM+患者结局显著更差。

要点

  • MDT后5年影像学无进展生存为23%,无转移生存为68%。
  • cN1患者5年无转移生存83% vs cM+患者51%(p<0.001)。
  • cN1中初次MDT时较高PSA与影像阳性淋巴结数为无转移生存的风险因素。

核心结论

  • MDT后5年随访时23%的患者未出现第二次复发。
  • cM+患者在无转移生存、无姑息性雄激素剥夺治疗生存和癌症特异性生存方面结局显著更差。
  • 转移复发的风险因素可用于患者咨询、告知预后并可能筛选MDT候选者。

研究设计与样本

  • 双中心回顾性研究,纳入2006至2020年间根治性前列腺切除术后因寡复发前列腺癌接受MDT的连续患者211例。
  • MDT包括立体定向体部放疗(SBRT)、挽救性淋巴结清扫(sLND)、全盆腔/腹膜后放疗(WP[R]RT)或转移灶切除。

主要发现

  • 211例中122例(58%)发生第二次复发;sLND 119例(56%),SBRT 48例(23%),WP(R)RT 31例(15%),转移灶切除11例(5%)。
  • 自根治性前列腺切除术后中位随访100个月,MDT后随访42个月。
  • MDT后5年影像学无进展生存、无转移生存、无雄激素剥夺治疗生存、无去势抵抗性前列腺癌生存、癌症特异性生存和总生存分别为23%、68%、58%、82%、93%和87%。
  • cN1(n=114)vs cM+(n=97)的5年无转移生存83% vs 51%(p<0.001),无姑息性雄激素剥夺治疗生存70% vs 49%(p=0.014),癌症特异性生存100% vs 86%(p=0.019)。
  • cN1中无转移生存的风险因素:根治性前列腺切除时较低初始PSA(HR 0.15,95%CI 0.02-1.02,p=0.053)、根治性前列腺切除时pN分期(HR 2.91,95%CI 0.83-10.24,p=0.096)、根治性前列腺切除后PSA未持续(HR 0.47,95%CI 0.19-1.12,p=0.089)、初次MDT时较高PSA(HR 2.38,95%CI 1.07-5.24,p=0.032)、影像阳性淋巴结数(HR 1.65,95%CI 1.14-2.40,p<0.01);cM+中无转移生存的风险因素:较高病理Gleason评分(HR 1.86,95%CI 0.93-3.73,p=0.078)、影像病灶数(HR 0.77,95%CI 0.57-1.04,p=0.083)、cM1b/cM1c(非淋巴结转移复发;HR 2.62,95%CI 1.58-4.34,p<0.001)。

关键数值与推荐

  • cN1(n=114)vs cM+(n=97)的5年无转移生存83% vs 51%(p<0.001)。
  • cN1(n=114)vs cM+(n=97)的无姑息性雄激素剥夺治疗生存70% vs 49%(p=0.014)。
  • cN1(n=114)vs cM+(n=97)的癌症特异性生存100% vs 86%(p=0.019)。
  • cN1中初次MDT时较高PSA的HR 2.38(95%CI 1.07-5.24,p=0.032),影像阳性淋巴结数的HR 1.65(95%CI 1.14-2.40,p<0.01)。
  • cM+中cM1b/cM1c(非淋巴结转移复发)的HR 2.62(95%CI 1.58-4.34,p<0.001)。

临床怎么用

  • 作者认为,转移复发的风险因素可用于咨询患者、告知预后并可能筛选MDT候选者。
  • 患者摘要指出,对影像检测到的淋巴结、骨或内脏复发(影像上最多五个复发病灶)采用局部个体化治疗,可延迟过早使用激素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastasis-directed therapy (MDT) is performed to delay systemic treatments for oligorecurrent disease after primary prostate cancer (PCa) treatment. OBJECTIVE: The aim of this study was to identify the predictors of therapeutic response of MDT for oligorecurrent PCa. DESIGN, SETTING, AND PARTICIPANTS: bicentric, retrospective study, including consecutive patients who underwent MDT for oligorecurrent PCa after radical prostatectomy (RP; 2006-2020) was conducted. MDT encompassed stereotactic body radiation therapy (SBRT), salvage lymph node dissection (sLND), whole-pelvis/retroperitoneal radiation therapy (WP[R]RT), or metastasectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ndpoints were 5-yr radiographic progression-free survival (rPFS), metastasis-free survival (MFS), palliative androgen deprivation treatment (pADT)-free survival, and overall survival (OS) together with prognostic factors for MFS following primary MDT. Survival outcomes were studied by Kaplan-Meier survival and univariable Cox regression (UVA). RESULTS AND LIMITATIONS: A total of 211 MDT patients were included; 122 (58%) developed a secondary recurrence. Salvage lymph node dissection was performed in 119 (56%), SBRT in 48 (23%), and WP(R)RT in 31 (15%) of the cases. Two patients received sLND + SBRT and one received sLND + WPRT. Eleven (5%) patients received metastasectomies. The median follow-up since RP was 100 mo, while follow-up after MDT was 42 mo. The 5-yr rPFS, MFS, androgen deprivation treatment(-free survival, castration-resistant prostate cancer-free survival, CSS, and OS after MDT were 23%, 68%, 58%, 82%, 93%, and 87% respectively. There was a statistically significant difference between cN1 (n = 114) and cM+ (n = 97) for 5-yr MFS (83% vs 51%, p < 0.001), pADT-free survival (70% vs 49%, p = 0.014), and CSS (100% vs 86%, p = 0.019). UVA was performed to assess the risk factors (RFs) for MFS in cN1 and cM+. Alpha was set at 10%. RFs for MFS in cN1 were lower initial prostate-specific antigen (PSA) at the time of RP (hazard ratio [95% confidence interval] 0.15 [0.02-1.02], p = 0.053], pN stage at RP (2.91 [0.83-10.24], p = 0.096), nonpersisting PSA after RP (0.47 [0.19-1.12], p = 0.089), higher PSA at primary MDT (2.38 [1.07-5.24], p = 0.032), and number of positive nodes on imaging (1.65 [1.14-2.40], p < 0.01). RFs for MFS in cM+ were higher pathological Gleason score (1.86 [0.93-3.73], p = 0.078), number of lesions on imaging (0.77 [0.57-1.04], p = 0.083), and cM1b/cM1c (non-nodal metastatic recurrence; 2.62 [1.58-4.34], p < 0.001). CONCLUSIONS: Following MDT, 23% of patients were free of a second recurrence at 5-yr follow-up. Moreover, cM+ patients had significantly worse outcomes in terms of MFS, pADT-free survival, and CSS. The RFs for a metastatic recurrence can be used for counseling patients, to inform prognosis, and potentially select candidates for MDT. PATIENT SUMMARY: In this paper, we looked at the outcomes of using localized, patient-tailored treatment for imaging-detected recurrent prostate cancer in lymph nodes, bone, or viscera (maximum five recurrences on imaging). Our results showed that targeted treatment of the metastatic lesions could delay the premature use of hormone therapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Milenkovic U, Kuijk J, Roussel E, et al. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy. Eur Urol Oncol. 2023. PMID: 36878753. doi:10.1016/j.euo.2023.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。